# Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

> **NCT03440112** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nicolaas Bohnen, MD, PhD** · enrollment: 34 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Clarithromycin (Not used as of 4/2020)
- **DRUG:** Placebo (Not used as of 4/2020)
- **DRUG:** Transdermal flumazenil (Added 4/2020)
- **DRUG:** Placebo (Added 4/2020)

## Key facts

- **NCT ID:** NCT03440112
- **Lead sponsor:** Nicolaas Bohnen, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-29
- **Primary completion:** 2021-12-08
- **Final completion:** 2021-12-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03440112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03440112, "Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03440112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*